Malaria biology and disease pathogenesis: insights for new treatments.
Malaria biology and disease pathogenesis: insights for new treatments.
复制标题
DOI：
10.1038/nm.3073
复制
发表时间：
2013-02
期刊：
影响因子：
82.9
通讯作者：
Wellems TE
中科院分区：
文献类型：
--
作者：
Miller LH;Ackerman HC;Su XZ;Wellems TE
恶性疟疾是一种由寄生原虫引起的传染病，仅在非洲每年就夺走了近100万儿童的生命，是最大的公共卫生问题。越来越多的证据表明，东南亚正在对青蒿素衍生物产生抗药性，青蒿素衍生物是治疗这种感染的无性血液期的一线疗法。消除疟疾的新举措将受益于扩大的抗疟疾药物系列，包括杀死循环中的恶性疟原虫配子细胞的新药，从而防止传播。我们目前对无性血液期寄生虫和配子体生物学的了解，以及在体外培养它们的能力，让我们乐观地认为，对大型化学库的高通量筛选将产生新一代抗疟疾药物。还需要新的治疗方法来降低严重疟疾的高死亡率。对严重疾病的病理生理学的了解可能会为提高存活率的药物确定合理的靶点。
Plasmodium falciparum malaria, an infectious disease caused by a parasitic protozoan, claims the lives of nearly a million children each year in Africa alone and is a top public health concern. Evidence is accumulating that resistance to artemisinin derivatives, the frontline therapy for the asexual blood stage of the infection, is developing in southeast Asia. Renewed initiatives to eliminate malaria will benefit from an expanded repertoire of antimalarials, including new drugs that kill circulating P. falciparum gametocytes, thereby preventing transmission. Our current understanding of the biology of asexual blood-stage parasites and gametocytes and the ability to culture them in vitro lends optimism that high-throughput screenings of large chemical libraries will produce a new generation of antimalarial drugs. There is also a need for new therapies to reduce the high mortality of severe malaria. An understanding of the pathophysiology of severe disease may identify rational targets for drugs that improve survival.